Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 183

Results For "Mark"

5374 News Found

Max Lab partners with Stepcare to expand in Bengaluru
Healthcare | July 23, 2025

Max Lab partners with Stepcare to expand in Bengaluru

This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas


Akums launches high-strength Paracetamol oral suspension 500mg/5ml
News | July 23, 2025

Akums launches high-strength Paracetamol oral suspension 500mg/5ml

Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats


Fortis and Gleneagles India deepen collaboration to drive growth
Healthcare | July 23, 2025

Fortis and Gleneagles India deepen collaboration to drive growth

Combined strength of two brands across 11 states to elevate patient care delivery and access to doctors


Syngene reports Q1 FY26 revenue higher at Rs. 875 Cr
News | July 23, 2025

Syngene reports Q1 FY26 revenue higher at Rs. 875 Cr

Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%


AstraZeneca plans to invest $50 billion in US by 2030
News | July 22, 2025

AstraZeneca plans to invest $50 billion in US by 2030

Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US


Roche updates on sBLA for Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
Clinical Trials | July 21, 2025

Roche updates on sBLA for Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population


Miltenyi Biotec and THSTI partner to launch CAR-T Cell and gene therapy training curriculum
News | July 21, 2025

Miltenyi Biotec and THSTI partner to launch CAR-T Cell and gene therapy training curriculum

This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.


Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
News | July 21, 2025

Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr

During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D


Bayer’s Nubeqa receives EU approval for patients with advanced prostate cancer
Drug Approval | July 21, 2025

Bayer’s Nubeqa receives EU approval for patients with advanced prostate cancer

European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)